[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351698-105":59,"doc-detail-351698-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","immunogenomic-classification-reveals-prognostic-immune-signatures-in-pediatric-solid-and-hematological-tumors","Immunogenomic classification reveals prognostic immune signatures in pediatric solid and hematological tumors","","Immune features in pediatric tumors remain insufficiently characterized. Immunogenomic analysis of public TARGET data examined pediatric solid tumor (PST, n=423) and pediatric hematological tumor (PHT, n=2302) samples, clustering them into immune subtypes (PST: S1–S5; PHT: H1–H4). In PST, S1 showed the poorest survival, whereas S4—down-regulating wound and B-cell signatures—predicted prolonged overall survival (HR=0.378, P\u003C0.001). The S4 subtype was validated in neuroblastoma (ZJUCH, n=127). In PHT, immune cluster–prognosis links differed by FLT3-ITD status in AML. Findings support immune features as prognostic biomarkers and inform treatment planning.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunogenomic-classification-reveals-prognostic-immune-signatures-in-pediatric-solid-and-hematological-tumors/351698/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunogenomic-classification-reveals-prognostic-immune-signatures-in-pediatric-solid-and-hematological-tumors/351698.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How were immune features analyzed in pediatric tumors?","Question",{"text":113,"@type":114},"Public TARGET immunogenomic data were used to characterize immune features, clustering PST and PHT samples into immune subtypes based on those features.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which PST immune subtype was associated with the worst and best outcomes?",{"text":118,"@type":114},"Cluster S1, with elevated Wound_CSR and B cell signatures, showed the worst overall survival, while cluster S4 with down-regulated features was linked to prolonged survival.",{"name":120,"@type":111,"acceptedAnswer":121},"How did immune cluster–prognosis relationships differ in PHT by AML FLT3-ITD status?",{"text":122,"@type":114},"In FLT3-ITD mutation-positive AML (AML-1), cluster H2 showed upregulated neutrophil/monocyte infiltration and antigen processing signatures with the worst overall survival; in FLT3-ITD mutation-negative AML (AML-2), cluster H2 showed favorable outcomes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351698,1790217884,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nImmunogenomic classification reveals prognostic immune signatures in pediatric solid and hematological tumors  \nZhouqi Xia1,2, Qiaoli Hua1,2, Jianqin Qian1, Jinhu Wang3,4,5,6, Jiangtao Liang7, Qiaojun He2,8,9􀀍, Shaoqing Ni1,2􀀍 & Ting Tao3,4,5,6􀀍  \nThe immune features in pediatric tumor are poorly explored. To characterize immune features of pediatric cancer, we performed an immunogenomic analysis of public database (TARGET) for pediatric solid tumor (PST) (n = 423) and pediatric hematological tumor (PHT) (n = 2302). We clustered PST and PHT samples into 5 subtypes (S1-S5) and 4 subtypes (H1-H4), respectively, based on immune features. In the PST cohort, cluster S1 with elevated expression of Wound_CSR (fibroblast core serum response in wound healing) and B cell signatures exhibited the worst overall survival. Conversely, cluster S4 (HR = 0.378, 95% CI: 0.24–0.59, P-value \u003C 0.001) with down-regulated expression of these features was associated with prolonged survival. We also validated the prognostic significance of the S4 immune subtype in an independent neuroblastoma cohort from the ZJUCH (n = 127), which demonstrated favorable patient outcomes. In the PHT cohort, we observed that the relationships between immune clusters and prognosis differed between FLT3-ITD mutation-positive AML (AML-1) and FLT3-ITDmutation-negative AML (AML-2) . InAML-1, cluster H2 featured upregulated infiltration of neutrophils, monocytes and antigen processing signatures, possibly leading to the worst overall survival. While inAML-2, cluster H2 exhibited a favorable outcome. The study highlights the potential of immune features as biomarkers for prognosis and treatment planning in pediatric cancers and provides novel insights into their immunological landscape.  \nKeywords Pediatric solid tumor, Pediatric hematological tumor, Immune features, Prognosis  \nAbbreviations  \nPST Pediatric solid tumor  \nPHT Pediatric hematological tumor  \nNB Neuroblastoma  \nAML Acute myeloid leukemia  \nTIME Tumor immune microenvironment  \nALL Acute lymphoblastic leukemia  \nOS Osteosarcoma  \nWT Wilms tumor  \n1National Clinical Trial Institute, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents’ Health and Diseases, Hangzhou 310052, Zhejiang, China. 2Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China. 3Pediatric Cancer Research Center, National Clinical Research Center for Children and Adolescents’Health and Diseases, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310052, Zhejiang, China. 4Department of Surgical Oncology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents’ Health and Diseases, Hangzhou 310052, Zhejiang, China.  \n5Zhejiang Key Laboratory of Neonatal Diseases, Hangzhou 310052, Zhejiang, China. 6Cancer Center, Zhejiang University, Hangzhou 310052, Zhejiang, China. 7Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou 310009, Zhejiang, China. 8Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China. 9Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China. 􀀍 email: [qiaojunhe@zju.edu.cn](qiaojunhe@zju.edu.cn);  \n[chgcp@zju.edu.cn](chgcp@zju.edu.cn); [taot@zju.edu.cn](taot@zju.edu.cn)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nRT  \nCCSK dbGaP NIH  \nTPM  \nFPKMssGSEA GSEs QuSAGE GO  \nKEGG  \nDAWT  \nFHWT  \nRhabdoid tumor  \nClear cell sarcoma of kidney Database of Genotypes and Phenotypes National Institutes of Health  \nTranscripts per kilobase of exon per million mapped reads Fragments per kilobase of exon per million mapped fragments  \nSingle-sampl","cbCaioObN8d3NmSQ","https://ap.wps.com/l/cbCaioObN8d3NmSQ","pdf",6986551,15,"English","# Introduction\n## Clinical burden and survival gaps\n## Limitations of existing therapies\n## Role of tumor immune microenvironment\n# Methods\n## Immunogenomic analysis using TARGET\n## Immune-feature clustering\n## Validation cohort\n## AML FLT3-ITD stratification\n# Results\n## PST immune subtypes and survival association\n## Neuroblastoma validation of S4\n## PHT immune subtypes differ by AML mutation status\n# Discussion\n## Immune features as prognostic biomarkers\n## Implications for treatment planning\n# Keywords and abbreviations\n## PST/PHT and major clinical terms","[{\"question\":\"How were immune features analyzed in pediatric tumors?\",\"answer\":\"Public TARGET immunogenomic data were used to characterize immune features, clustering PST and PHT samples into immune subtypes based on those features.\"},{\"question\":\"Which PST immune subtype was associated with the worst and best outcomes?\",\"answer\":\"Cluster S1, with elevated Wound_CSR and B cell signatures, showed the worst overall survival, while cluster S4 with down-regulated features was linked to prolonged survival.\"},{\"question\":\"How did immune cluster–prognosis relationships differ in PHT by AML FLT3-ITD status?\",\"answer\":\"In FLT3-ITD mutation-positive AML (AML-1), cluster H2 showed upregulated neutrophil/monocyte infiltration and antigen processing signatures with the worst overall survival; in FLT3-ITD mutation-negative AML (AML-2), cluster H2 showed favorable outcomes.\"}]","Immunogenomic classification reveals prognostic immune signatures in pediatric solid and hematological tumors | PDF",1790095388,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86fe9fe010e401595a6aa505e479a40e.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2793e63275f2872383ca0165c01a0de.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/853801939108c5f8a1fba12de15f2359.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d5bcef745c82b5123f9fda6edd81fad.webp",980,1287]